Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Contract Win

20 Jul 2005 08:30

Angle PLC20 July 2005 For Immediate Release 20 July 2005 ANGLE plc Wins Contract With The BioBusiness Alliance of Minnesota ANGLE plc, the venture management and consulting company specialising in thecommercialisation of technology and the development of technology-based industryis pleased to announce that its US Consulting and Management division has won acontract with The BioBusiness Alliance of Minnesota, worth $200,000, to conducta comprehensive assessment of the state's biobusiness capabilities. The BioBusiness Alliance of Minnesota is an industry-driven, businessdevelopment organisation of representatives from established and emergingMinnesota companies, universities and government. It is devoted to building thebioscience industry, retaining and creating jobs and economic growth, andpositioning Minnesota as a global leader in biobusiness. The Minnesotabiobusiness industry includes many World-class businesses and institutions suchMedtronic, 3M and the Mayo Clinic. The information from the six month assessment, which will conclude in the fourthquarter of 2005, will benchmark Minnesota against other countries and states.The outcome of the process will identify the State's strengths and developmentneeds, and provide recommendations to target specific areas of biobusiness inwhich Minnesota can compete as a global leader. These recommendations willreflect the convergence of technologies, products, and markets that exist in theState, and identify Minnesota's opportunity areas for growth. ANGLE established a Minnesota office in August 2004 in recognition of thesignificant business potential it believes exists in this State. ANGLE waschosen following a rigorous national and international selection process. ANGLEwas selected for their significant experience both in conducting assessments inthe U.S. and internationally, and for their consulting expertise in thetechnology industry. Dr. Gary P. Evans, CEO of ANGLE's US Operations, said: "We are delighted that ANGLE has been selected to deliver this innovative,industry-driven assessment of Minnesota's biobusiness capabilities. We lookforward to working with the BioBusiness Alliance team to take the first step inthe long-term planning and development of a biobusiness strategy for Minnesota." Andrew Newland, Chief Executive of ANGLE plc, said: "This contract is a great example of ANGLE's continuing expansion within theUnited States. The Minnesota region is a prosperous biobusiness arena and thiscontract will position ANGLE alongside some of the biggest names in the market.We expect that Minnesota will emerge as a further key platform for our Venturesbusiness in the US." - ENDS - For further information ANGLE plcAndrew Newland, Chief Executive Tel: +44(0)1483 295830Lisa Smith, Principal Executive, US Operations Tel: +1 301 524 5654 Buchanan Communications Tel: +44 (0)20 7466 5000Richard Darby, Suzanne Brocks, James Strong Notes to EditorsFounded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. This includes extensiveexpertise in the commercialization of technology, new company formation,investment and corporate finance, Research Park and incubator development andmanagement, and delivery of economic development programs. ANGLE operates fromoffices in the UK, the US and the Middle East. ANGLE is listed on AIM (AGL.L); further information can be found onwww.ANGLEplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
15th Feb 20105:41 pmRNSHolding(s) in Company
2nd Feb 20101:38 pmRNSHolding(s) in Company
1st Feb 20101:30 pmRNSHolding(s) in Company
29th Jan 20103:14 pmRNSHolding(s) in Company
22nd Jan 20108:49 amRNSHolding(s) in Company
21st Jan 20107:00 amRNSInterim Results
6th Jan 20107:00 amRNSNotice of Interim Results
27th Nov 20097:00 amRNSContract Win
28th Sep 20094:48 pmRNSHolding(s) in Company
24th Sep 20097:40 amRNSDirector/PDMR Shareholding
10th Sep 20093:32 pmRNSResult of AGM
3rd Sep 20094:18 pmRNSHolding(s) in Company
26th Aug 20093:08 pmRNSDisposal of Provexis Holding
12th Aug 20091:40 pmRNSHolding(s) in Company
11th Aug 20094:22 pmRNSHolding(s) in Company
24th Jul 20097:00 amRNSPreliminary Results
2nd Jul 20094:44 pmRNSHolding(s) in Company
11th Jun 20092:21 pmRNSHolding(s) in Company
30th Mar 20095:47 pmRNSDirector/PDMR Shareholding
26th Feb 20097:00 amRNSNovocellus contract completion
11th Feb 20091:44 pmRNSHolding(s) in Company
29th Jan 20097:00 amRNSInterim Results
22nd Jan 20093:09 pmRNSNotice of Results
12th Jan 20097:00 amRNSNovocellus deal
5th Dec 20082:31 pmRNSChange of Registered Address
24th Oct 20084:14 pmRNSAnnual Report & Accounts
22nd Oct 20083:04 pmRNSHolding(s) in Company
12th Sep 20084:43 pmRNSOffer Update
11th Sep 20083:21 pmRNSResult of AGM
11th Sep 20082:46 pmRNSRule 8.3- Angle Plc
10th Sep 200812:48 pmRNSRule 8.3- Angle Plc
5th Sep 20081:23 pmRNSRule 8.3- Angle PLC
28th Aug 200812:51 pmRNSRule 8.3- Angle Plc
27th Aug 20081:05 pmRNSRule 8.3- Angle Plc
22nd Aug 200812:13 pmRNSRule 8.3- Angle Plc
21st Aug 20088:40 amRNSStatement re: Angle Plc
4th Aug 20087:00 amRNSProvexis Fundraising
29th Jul 200811:39 amRNSRule 8.3- Angle Plc
23rd Jul 20082:13 pmRNSRule 8.3- Angle Plc
18th Jul 20085:19 pmRNSRule 2.10 Announcement
18th Jul 20083:09 pmRNSResponse RE Angle Offer
18th Jul 20087:00 amRNSStatement re possible offer
11th Jul 20081:05 pmRNSStatement re. announcement
11th Jul 20088:10 amRNSOffer Update
10th Jul 20087:00 amRNSParsortix world break-through
10th Jul 20087:00 amRNSAguru Images sales
10th Jul 20087:00 amRNSContract Win
10th Jul 20087:00 amRNSPreliminary Results
19th Jun 200811:37 amRNSRule 8.3- Angle Plc
10th Jun 200812:27 pmRNSRule 8.3- Angle Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.